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Algorithm for the treatment of NSCLC in 2014 
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Non-Small Cell Lung Cancer (NSCLC) 
Stages IB to IIIA 
Hotta, K. et al. J Clin Oncol 22:3860-3867, 2004 
Surgery versus Surgery and adjuvant CT (Overall Survival) 
Miksad RA et al. J Clin Oncol 27:2245-2252, 2009 
Adjuvant CT regimens 
(Meta-analysis of Overall Survival) 
Non-Small Cell Lung Cancer (NSCLC) 
Stages IIIA and IIIB 
Stages IIIA and IIIB 
Represents very different diseases 
Furuse K et al. J Clin Oncol 17:2692-2699, 1999 
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Patterns of recurrence post RT / CT 
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Stages IIIA and IIIB 
Factors influencing the choice of treatment 
Stage of disease 
Age 
Performance status 
Weigth loss 
Co-morbidities 
Structural conditions of the Center 
Stages IIIA and IIIB 
Progress achieved 
Trial Median OS 3-Y OS 
CALGB 8433 RT   9.6 mo 10% 
CALGB 8433 Seq C - RT 13.7 mo 24% 
RTOG 9410 Seq C (Vinb/CisP) - RT 14.6 mo 31% 
RTOG 9410 Con C (Vinb/CisP) - RT 17.1 mo 37% 
RTOG 9410 Con C (Etop/CisP) - RT 19.6 mo 40% 
SWOG 9504 Con C - RT → D 27.0 mo 40% 
Progression after therapy 
Adjuvant CT regimens 
Adjuvant CT regimens 
Considerations for first-line therapy 
• Performance status 
• Age 
• Organ function, nutritional status 
- Hemoptysis 
• Histology 
• Molecular variables 
• Other 
- CNS metastases 
• Previous chemotherapy in adjuvant or locally advanced setting 
- Response and adverse events 
- Time from previous treatment 
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EFGR and ALK negative 
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Updated from Gandara DR, et al. Clin Lung Cancer 10:392-394, 2009 
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Algorithm for the treatment of advanced NSCLC in 2014 
Cisplatin 
• Pharmacologic category: Alkylating agent 
• Mechanism of action: Inhibits DNA synthesis by the formation of DNA cross-links. 
 No specific of cell cycle. 
• Excretion: Urine (>90%), feces (10%) 
• Frequent Adverse Reactions: 
- Nausea and vomiting 
- Myelosuppression 
- Renal impairment 
- Neurotoxicity (peripheral neuropathy is dose- and duration-dependent) 
- Endocrine & metabolic: hypokalemia, hypomagnesemia 
Carboplatin 
• Pharmacologic category: Alkylating agent 
• Mechanism of action: Covalently binds to DNA, possible cross-linking and interfere 
with the function of DNA. No specific of cell cycle. 
• Excretion: Urine (60 - 90%) 
• Frequent Adverse Reactions: 
- Nausea, vomiting, mucositis 
- Myelosuppression (dose related and dose-limiting) 
- Renal impairment 
- Endocrine & metabolic: hypokalemia, hypomagnesemia 
- Hepatic (elevated liver function tests) 
Vinorelbine 
• Pharmacologic category: Vinca alkaloid 
• Mechanism of action: Binds to tubulin and inhibits microtubule formation, arresting the 
cell at metaphase 
• Excretion: Feces (46%), urine (18%) 
• Frequent Adverse Reactions: 
- Nausea, vomiting 
- Myelosuppression (dose-limiting) 
- Hepatic (elevated liver function tests) 
- Neuromuscular & skeletal – weakness, peripheral neuropathy 
Gemcitabine 
• Pharmacologic category: Antimetabolite (pyrimidine antagonist) 
• Mechanism of action: Inhibits DNA synthesis by inhibition of DNA polymerase and 
ribonucleotide reductase; specific for the S-phase of the cycle 
• Excretion: Urine (99%), feces (>1%) 
• Frequent Adverse Reactions: 
- Nausea, vomiting 
- Central nervous system: pain, fever 
- Myelosuppression (dose-limiting) 
- Hepatic (elevated liver function tests) 
Docetaxel 
• Pharmacologic category: Taxane, antimicrotubular, 
 natural antineoplastic agent, isolated from the needles of the European yew. 
• Mechanism of action: Promotes the assembly of microtubules from tubulin dimers, and 
inhibits the depolymerization of tubulin; most activity occurs during the M-phase of the 
cycle  
• Excretion: Feces (75%), urine (6%) 
• Frequent Adverse Reactions: 
- Mucositis/stomatitis (may be dose-limiting), nausea, vomiting 
- Cardiovascular – fluid retention (more common at cumulative doses ≥ 400 mg/m2) 
- Myelosuppression 
- Hypersensitivity reactions 
Paclitaxel 
• Pharmacologic category: Taxane, antimicrotubular, 
 natural antineoplastic agent, isolated from the bark of the Pacific yew, Taxus brevifolia 
• Mechanism of action: Promotes the microtubules assembly by enhancing the action of 
tubulin dimers, and inhibiting their disassembly; interfere with the late G2 mitotic phase; 
can distort mitotic spindles, resulting in the breakage of chromossomes 
• Excretion: Feces (+/- 70%), urine (14%) 
• Frequent Adverse Reactions: 
- Mucositis (may be dose-limiting), stomatitis (more common at doses > 390 mg/m2) 
- Allergic (nonimmunologically mediated release of histamine and other vasoactive 
substances) 
- Cardiovascular – bradycardia transient 
- Myelosuppression 
- Neurotoxicity – sensory and autonomic neuropathy, myopathy and CNS toxicity – 
may be cumulative and dose-limiting (doses > 250 mg/m2) 
Pemetrexed 
• Pharmacologic category: Antimetabolite (antifolate) 
• Mechanism of action: Inhibits thymidilate synthase (TS), dihydrofolate reductase 
(DHFR), glycinamide ribonucleotide formyltransferase (GARFT) and aminoimidazole 
carboxamide ribonucleotide formyltransferase (AICARFT), enzymes involved in folate 
metabolism and DNA synthesis, resulting in inhibition of purine and thymidine 
nucleotide and protein synthesis 
• Excretion: Urine (70 – 90 %) 
• Frequent Adverse Reactions: 
- Cardiovascular – chest pain, edema 
- CNS - fatigue 
- Gastrointestinal – nausea, vomiting 
- Myelosuppression 
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